Encompass Health Posts 3Q EPS of $1.50
EHC sits 32% above its 52-week low of $92.77.
Summary
Encompass Health reported third-quarter EPS of $1.50, with adjusted EPS of $1.52 and continuing-operations EPS of $1.51, on net income of $149.9M and revenue of $1.61B. That compares with $1.54 diluted EPS in Q2, when revenue rose 9.6% to $1.6B and the company raised full-year guidance and lifted the dividend to $0.21 a share. The headline carries no guidance or comparison to consensus, so the print alone doesn't establish a beat or miss. Context worth keeping in mind: the CEO sold $21.7M of stock near the 52-week high in August, and the company has an active $1B buyback plus a universal shelf on file. Adjusted EBITDA and any guidance update will determine whether this holds the post-Q2 narrative.
At the time of this announcement, EHC was trading at $122.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12B. The 52-week trading range was $92.77 to $129.96. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.